EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms

Raanan Greenman iD, Chris J Weston iD

Cells · 13.01.2025 · 14 (2) · 105

DOI: 10.3390/cells14020105 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 13.01.2025. Verfasst von Raanan Greenman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel. Hauptthemen laut MEDLINE: Fibrosis, Chemokine CCL24. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissue fibrosis results from a dysregulated and chronic wound healing response accompanied by chronic inflammation and angiogenesis. Regardless of the affected organ, fibrosis shares the following common hallmarks: the recruitment of immune cells, fibroblast activation/proliferation, and excessive extracellular matrix deposition. Chemokines play a pivotal role in initiating and advancing these fibrotic processes. CCL24 (eotaxin-2) is a chemokine secreted by immune cells and epithelial cells, which promotes the trafficking of immune cells and the activation of profibrotic cells through CCR3 receptor binding. Higher levels of CCL24 and CCR3 were found in the tissue and sera of patients with fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and metabolic dysfunction-associated steatohepatitis (MASH). This review delves into the intricate role of CCL24 in fibrotic diseases, highlighting its impact on fibrotic, immune, and vascular pathways. We focus on the preclinical and clinical evidence supporting the therapeutic potential of blocking CCL24 in diseases that involve excessive inflammation and fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisChemokine CCL24HumansAnimalsInflammation

Stichwörter der Autor:innen

CCL24CCR3chemokineeotaxin-2fibrosismetabolic dysfunction-associated steatohepatitisprimary sclerosing cholangitissystemic sclerosis

Substanzen

Chemokine CCL24

Autor:innen und Institutionen

  • Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
  • Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
  • National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham B15 2TT, UK.

ORCID-Profile: Raanan Greenman, Chris J Weston

Förderung

  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC)

Zitieren

APA

Greenman, R., & Weston, C. J. (2025). CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms. Cells, 14(2), 105. https://doi.org/10.3390/cells14020105

Vancouver

Greenman R, Weston CJ. CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms. Cells. 2025;14(2):105. doi:10.3390/cells14020105

BibTeX
@article{Greenman2025,
  author = {Greenman, Raanan and Weston, Chris J},
  title = {CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {105},
  doi = {10.3390/cells14020105}
}
Kostenlos starten →